ID   SNU-C5/5FU-R
AC   CVCL_V482
DR   Wikidata; Q54955296
RX   PubMed=17845510;
CC   Population: Korean.
CC   Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Leu (c.652G>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (from parent cell line).
CC   Derived from sampling site: Cecum.
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_5112 ! SNU-C5
SX   Female
AG   77Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 20-05-21; Version: 7
//
RX   PubMed=17845510; DOI=10.1111/j.1742-7843.2007.00115.x;
RA   Jung G.-R., Kim K.-J., Choi C.-H., Lee T.-B., Han S.I., Han H.-K.,
RA   Lim S.-C.;
RT   "Effect of betulinic acid on anticancer drug-resistant colon cancer
RT   cells.";
RL   Basic Clin. Pharmacol. Toxicol. 101:277-285(2007).
//